Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : DP Technology
Deal Size : Undisclosed
Deal Type : Collaboration
DP Technology Collaborates with Lepu Biopharma to Boost ADC Drug Innovation
Details : The partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform and advancing the candidate ADC to the clinical stage.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 21, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : DP Technology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Puyouheng (pucotenlimab injection) is a humanized IgG4 monoclonal antibody against human PD-1, bind to PD-1 with high affinity to restore the ability of immune cells to kill cancer cells by blocking the binding of PD-1 to its ligands PD-L1 and PD-L2.
Brand Name : Puyouheng
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 25, 2022
LOOKING FOR A SUPPLIER?
Reset All
